NCT03158792View on ClinicalTrials.gov

Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 24, 2015

Primary Completion Date

July 13, 2017

Study Completion Date

July 13, 2017

Conditions
Venous ThromboembolismRenal Impairment
Interventions
DRUG

Enoxaparin 20Mg/0.2mL Prefilled Syringe

Enoxaparin 20mg subcutaneously once daily

DRUG

Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml

Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered

Trial Locations (1)

Unknown

LAU Medical Center-Rizk Hospital, Beirut

All Listed Sponsors
lead

Lebanese American University

OTHER

NCT03158792 - Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function | Biotech Hunter | Biotech Hunter